Nektar Therapeutics (NASDAQ: NKTR) stock closed at $35.98 on 9/4/25 after a major increase of 26.0%. Moreover, exceptionally high trading volume at 333% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months and has risen 25.0% during the last week.
Current PriceTarget Research Rating
Nektar Therapeutics has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Nektar Therapeutics has a very low Appreciation Score of 1 but a very high Power Rating of 90, triggering the Low Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment